Emerald Health Therapeutics Appoints Agro-Biotech President
November 22 2018 - 7:00AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH;
OTCQX:EMHTF) (“Emerald”) today announced that Thierry Schmidt has
been appointed President of Agro-Biotech, its Québec-based licensed
cannabis production operation, effective November 26, 2018. Mr.
Schmidt brings 20 years of experience in marketing, brand advocacy,
and general management; he has held senior leadership positions at
Next Level Energy Inc., L’Oréal Canada, and British American
Tobacco.
“We welcome Thierry to Agro-Biotech. As a
born-and-raised Francophone with deep consumer goods business and
marketing expertise, Thierry is ideally positioned to advance
Agro-Biotech’s strategy to serve patients and consumers in Quebec,”
said Mr. Chris Wagner, CEO, Emerald Health Therapeutics.
“Agro-Biotech and Emerald stand out in the
cannabis industry for their extensive experience in life sciences
as well as cannabis cultivation and marketing,” said Mr. Schmidt.
“I look forward to driving a highly competitive production and
product strategy for Agro-Biotech.”
Mr. Schmidt is a seasoned marketing executive
leader with extensive experience in the consumer goods industry. He
has held leadership and senior management positions in new business
development, operations, sales, investor relations, and
brand/consumer development. As General Manager at L’Oréal and Chief
Marketing Officer at Next Level Energy Inc., he managed product
development focused on developing a sustainable and profitable
business model as well as brand advocacy. Furthermore, in his
Business Development and Sales Director roles at British American
Tobacco, he successfully developed and launched a national trade
marketing strategy.
Mr. Schmidt has been granted an option to
acquire up to 125,000 common shares vesting over three years.
About Emerald Health Therapeutics,
Inc.
Emerald Health Therapeutics, Inc. (TSXV: EMH;
OTCQX: EMHTF; Frankfurt: TBD) is a Canadian licensed producer of
cannabis. Its 50%-owned Pure Sunfarms joint venture in BC is
completing a sophisticated 1.1 million square feet greenhouse; its
Agro-Biotech operation in Québec is completing a 75,000 square feet
indoor facility. Commercial production is expanding in both
facilities. It secured approximately 500 acres of hemp harvest in
2018 and has contracted for approximately 1000 acres in 2019 to
2022 with the goal of extracting low-cost cannabidiol (CBD).
Emerald’s team is highly experienced in life sciences, product
development, large-scale agri-business, and marketing, and is
focused on developing proprietary, value-added cannabis products
for medical and adult-use customers. Emerald is part of the Emerald
Health group, which is broadly focused on developing
pharmaceutical, botanical, and nutraceutical products that may
provide wellness and medical benefits by interacting with the human
body’s endocannabinoid system.
Please visit www.emeraldhealth.ca for more
information or contact:
Rob Hill, Chief Financial Officer(800) 757 3536
Ext. #5
Ray Lagace, Investor Relations Manager(800) 757
3536 Ext. #5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include production capacity of various facilities; expansion of
facilities; implementation of business strategies; and anticipated
production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, failure to obtain regulatory approvals;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; as well as the risk factors described in the
Company’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Jul 2023 to Jul 2024